Global cell-based assay market projections indicate that Asia/Pacific is expected to grow the fastest from 2019-2026.

 The global cell-based assay market is expected to reach approximately USD 13.10 billion by the year 2026, growing at a reasonable growth rate of more than 6.30%. Cell-based testing is a method of cell-based processing based on different parameters. Functional cells as screening instruments for testing on novel drugs are used in cell-based assessments. Cell-based tests can also assist in cell motility measurement, proliferation, and study in the fields of stem cells, immunology, cancer, and others. In addition, increased incidence of chronic diseases and lifestyle conditions and the use of high-performance test approaches led to a cell-based assessment over the projected period. In 2015, 133 million US deaths and disabilities were caused by chronic diseases, the association for the fight against chronic illnesses said. 

It is projected that at least one chronic illness affects 45 percent of the American population. In addition, the acceptance and demand for cell-based testing are expected to grow with the growing investments in research and development for drug finding. But high maintenance and operating costs hinder demand growth during the 2019-2026 projected timeframe.

For main areas, such as Asia Pacific, North America, Europe, Latin America, and the rest of the world, a geographical overview of the global assay market is considered. America, thanks to the well-established healthcare industry and the high level of use of cell-based therapies, is worldwide leading/important in terms of market share. In addition, the fastest growth rate / CAGR in the Asia-Pacific is expected to occur during the 2019-2026 projections. Rising R&D spending involves life science research and outsourcing drug discovery, including technology development, which may provide profitable growth opportunities for the Asia-Pacific cell-based assays industry.

Cell-based assays are commonly used for the exploration of drugs and the high-performance screening of compounds due to the benefits of predictability, automation possibilities, multiplexing, and miniaturization. They are very useful in the early phases of drug development.